Empirical therapy advisor

Before culture results are back: how likely is each antibiotic to cover the pathogen of a patient like this one, in this ward, given the last 12 months of results and today's alerts.

Patient

More options · any onset · target 80 % · 2026-07-19
Based on 1116 first isolates · ED · Cystitis (lower UTI) · 2025-07-20 → 2026-07-19
Emergency department
Per-organism detail: ED urine resistance view →
Narrowest option reaching 80 % coverage, no active warning
nitrofurantoin 84 % (81 %–86 %)
No tissue or blood levels: cystitis only.
Not covered: Proteus mirabilis (7 %), Pseudomonas aeruginosa (6 %), Klebsiella pneumoniae (3 %)
AntibioticCoverage, 12 months (95 % CI)12 mo4 wk
meropenem MEM
trend · Escherichia coli reserve
84 %
87 %
n = 77
nitrofurantoin NIT
trend · Escherichia coli lower UTI only
84 %
86 %
n = 77
piperacillin-tazobactam TZP
trend · Escherichia coli broad spectrum
80 %
81 %
n = 77
ciprofloxacin CIP
trend · Escherichia coli
78 %
84 %
n = 77
mecillinam MEC
trend · Escherichia coli lower UTI only
77 %
81 %
n = 77
ceftriaxone CRO
trend · Escherichia coli
76 %
77 %
n = 77
trimethoprim TMP
trend · Escherichia coli lower UTI only
72 %
75 %
n = 77
71 %
69 %
n = 77
52 %
53 %
n = 77
vancomycin VAN
trend · Enterococcus faecalis Gram-positive only
13 %
5 %
n = 77
5 %
4 %
n = 77
clindamycin CLI
trend · Staphylococcus aureus Gram-positive only
3 %
0 %
n = 77

Most likely organisms for this profile

Escherichia coli
54 %
Enterococcus faecalis
10 %
Klebsiella pneumoniae
10 %
Proteus mirabilis
7 %
Pseudomonas aeruginosa
6 %
Citrobacter freundii
4 %

Decision support only: coverage is the share of first isolates from similar patients that were susceptible (an organism not tested for a drug counts as not covered). It does not replace local treatment guidelines, allergy and severity assessment, or clinical judgement. The black tick on each bar is the coverage target; the bracket is the 95 % confidence interval.

AEI · Tyks Laboratoriot × Mylab · JunctionX Turku. Synteettinen aineisto; EARS-Net-luvut: ECDC.